Oral Tofacitinib for Refractory Lichen Planus Pigmentosus Coexisting with Frontal Fibrosing Alopecia

This article discusses the use of oral tofacitinib in treating a 48-year-old woman with refractory Lichen Planus Pigmentosus (LPPigm) and coexisting Frontal Fibrosing Alopecia (FFA). The patient, who had not responded to previous treatments, showed significant improvement with tofacitinib, experiencing near-complete resolution of hyperpigmentation and cessation of hairline recession over 18 months. The treatment was well-tolerated with no adverse effects, and the patient remained in remission one year after stopping the medication. The study suggests that tofacitinib could be a promising treatment for these challenging conditions, although further research is needed to confirm its efficacy and safety.